Skip to content
Screener

Vera Therapeutics VERA Cash & Equivalents

Cash & Equivalents at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$7.85B+57.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$78.36M+26.6%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$179.83M+239%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$8.36M-71.2%
Jade Biosciences logo
Jade BiosciencesJBIO
$55.09M+24.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$164.99M+40.6%

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.3B+87.1%
Enterprise value$2.26B+79.7%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:33 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212143
Line itemMarch 31, 2026December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents$114,351$354,725
Marketable securities482,409359,864
Prepaid expenses and other assets, current19,04214,294
Total current assets615,802728,883
Other assets, noncurrent5,9375,850

Item 1. Financial Statements

FAQ

What is Vera Therapeutics's cash & equivalents?
Vera Therapeutics (VERA) reported cash & equivalents of $114.35M in Q1 2026.
How has Vera Therapeutics's cash & equivalents changed year-over-year?
Vera Therapeutics's cash & equivalents increased by 107.6% year-over-year, from $55.09M to $114.35M.
What is the long-term trend for Vera Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Vera Therapeutics's cash & equivalents has grown at a 45.7% compound annual growth rate (CAGR), from $54M to $354.73M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Vera Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude